8U5 Stock Overview
Engages in the production and sale of biochemicals in Australia, France, the United Kingdom, Belgium, and Norway.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Circa Group AS Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NOK 0.35 |
52 Week High | NOK 0.35 |
52 Week Low | NOK 0.34 |
Beta | 0.20 |
11 Month Change | 0% |
3 Month Change | -0.57% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -79.83% |
Recent News & Updates
Recent updates
Shareholder Returns
8U5 | DE Chemicals | DE Market | |
---|---|---|---|
7D | 0% | -1.7% | -0.5% |
1Y | n/a | 3.8% | 1.6% |
Return vs Industry: Insufficient data to determine how 8U5 performed against the German Chemicals industry.
Return vs Market: Insufficient data to determine how 8U5 performed against the German Market.
Price Volatility
8U5 volatility | |
---|---|
8U5 Average Weekly Movement | n/a |
Chemicals Industry Average Movement | 4.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.5% |
10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 8U5 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 8U5's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 18 | Tony Duncan | www.circa-group.com |
Circa Group AS engages in producing bio-based chemicals in Australia, France, the United Kingdom, Belgium, and Norway. The company extracts value from non-food waste biomass to produce bio-based chemicals through its proprietary Furacell process. Its products include Cyrene, a polar aprotic solvent; and Levoglucosenone derivatives.
Circa Group AS Fundamentals Summary
8U5 fundamental statistics | |
---|---|
Market cap | €40.59m |
Earnings (TTM) | -€5.55m |
Revenue (TTM) | €1.65m |
24.6x
P/S Ratio-7.3x
P/E RatioIs 8U5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
8U5 income statement (TTM) | |
---|---|
Revenue | €1.65m |
Cost of Revenue | €539.46k |
Gross Profit | €1.11m |
Other Expenses | €6.66m |
Earnings | -€5.55m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Nov 09, 2023
Earnings per share (EPS) | -0.046 |
Gross Margin | 67.34% |
Net Profit Margin | -336.16% |
Debt/Equity Ratio | 0% |
How did 8U5 perform over the long term?
See historical performance and comparison